Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CYT Stock Summary
In the News
Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 inhibitor being investigated in combination with chemotherapy drugs. The drug has shown monotherapy activity in a phase 1 trial, but further development has been suspended.
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. Morgan Stanley 20th Annual Global Healthcare Conference Date: Wednesday, September 14 Time:
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript
Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The a
Cyteir Therapeutics Selected to Join Russell 2000® Index
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US market opens on September 20, as part of the 2021 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 300
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET. A live webcast of the fireside chat will be available in the I
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually on August 10, 2021. 12th Annual Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 10 Time: 11:30 AM EDT Panel: Syn
Cyteir Therapeutics Announces Closing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional
CYT Financial details
CYT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | |
Net income per share | -0.77 | -0.87 | -2.14 | -1.25 | |
Operating cash flow per share | -0.9 | -0.78 | -1.85 | -1.21 | |
Free cash flow per share | -0.91 | -0.81 | -1.91 | -1.21 | |
Cash per share | 1.49 | 0.46 | 9.73 | 4.17 | |
Book value per share | -1.46 | -2.01 | 9.61 | 4.15 | |
Tangible book value per share | -1.46 | -2.01 | 9.61 | 4.15 | |
Share holders equity per share | -1.46 | -2.01 | 9.61 | 4.15 | |
Interest debt per share | 0 | 0 | 0 | 0.01 | |
Market cap | 338.14M | 415.69M | 221.71M | 58.2M | |
Enterprise value | 309.13M | 404.75M | 31.98M | -88.03M | |
P/E ratio | -22.48 | -19.96 | -5.32 | -1.32 | |
Price to sales ratio | 42.27K | 0 | 0 | 0 | |
POCF ratio | -19.26 | -22.42 | -6.15 | -1.37 | |
PFCF ratio | -19.12 | -21.44 | -5.96 | -1.36 | |
P/B Ratio | -11.93 | -8.65 | 1.18 | 0.4 | |
PTB ratio | -11.93 | -8.65 | 1.18 | 0.4 | |
EV to sales | 38.64K | 0 | 0 | 0 | |
Enterprise value over EBITDA | -19.45 | -19.66 | -0.76 | 1.83 | |
EV to operating cash flow | -17.61 | -21.83 | -0.89 | 2.07 | |
EV to free cash flow | -17.47 | -20.88 | -0.86 | 2.05 | |
Earnings yield | -0.04 | -0.05 | -0.19 | -0.76 | |
Free cash flow yield | -0.05 | -0.05 | -0.17 | -0.74 | |
Debt to equity | 0 | 0 | 0 | 0.01 | |
Debt to assets | 0 | 0 | 0 | 0.01 | |
Net debt to EBITDA | 1.83 | 0.53 | 4.49 | 3.04 | |
Current ratio | 15.43 | 3.87 | 25.71 | 28.07 | |
Interest coverage | 0 | 0 | 0 | 72.11 | |
Income quality | 1.17 | 0.89 | 0.86 | 0.92 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 418.13 | 0 | 0 | 0 | |
Research and developement to revenue | 1.6K | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.05 | 0.03 | 0.01 | |
Capex to revenue | -16.63 | 0 | 0 | 0 | |
Capex to depreciation | -0.62 | -2.42 | -2.48 | -0.47 | |
Stock based compensation to revenue | 30.88 | 0 | 0 | 0 | |
Graham number | 5.04 | 6.28 | 21.48 | 10.78 | |
ROIC | 0.57 | 0.44 | -0.22 | -0.31 | |
Return on tangible assets | -0.48 | -1.52 | -0.21 | -0.29 | |
Graham Net | -1.54 | -2.13 | 9.32 | 3.97 | |
Working capital | 28.47M | 8.99M | 185.57M | 143.89M | |
Tangible asset value | -28.34M | -48.03M | 187.29M | 146.29M | |
Net current asset value | -29.27M | -49.64M | 184.98M | 142.26M | |
Invested capital | 0 | 0 | 0 | 0.01 | |
Average receivables | 0 | 113.5K | 50.5K | 19K | |
Average payables | 0 | 1.15M | 1.74M | 1.46M | |
Average inventory | 0 | 598.5K | -50.5K | -19K | |
Days sales outstanding | 7.48K | 0 | 0 | 0 | |
Days payables outstanding | 17.32K | 1.76K | 1.36K | 299.43 | |
Days of inventory on hand | 36.24K | -65.51 | -28.96 | 0 | |
Receivables turnover | 0.05 | 0 | 0 | 0 | |
Payables turnover | 0.02 | 0.21 | 0.27 | 1.22 | |
Inventory turnover | 0.01 | -5.57 | -12.61 | 0 | |
ROE | 0.53 | 0.43 | -0.22 | -0.3 | |
Capex per share | -0.01 | -0.04 | -0.06 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.29 | -0.21 | -0.32 | -0.24 | -0.1 | |
Operating cash flow per share | -0.36 | -0.2 | -0.29 | -0.12 | -0.13 | |
Free cash flow per share | -0.36 | -0.2 | -0.29 | -0.12 | -0.13 | |
Cash per share | 4.36 | 4.16 | 3.86 | 3.74 | 3.59 | |
Book value per share | 4.36 | 4.14 | 3.79 | 3.58 | 3.47 | |
Tangible book value per share | 4.36 | 4.14 | 3.79 | 3.58 | 3.47 | |
Share holders equity per share | 4.36 | 4.14 | 3.79 | 3.58 | 3.47 | |
Interest debt per share | 0.01 | 0.02 | -0.02 | 0 | 0 | |
Market cap | 67.83M | 58.37M | 64.77M | 92.93M | 102.33M | |
Enterprise value | -85.16M | -87.86M | -72.34M | -40.64M | -26.9M | |
P/E ratio | -1.64 | -1.97 | -1.4 | -2.76 | -7.24 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -5.4 | -8.44 | -6.37 | -22.4 | -22.46 | |
PFCF ratio | -5.39 | -8.09 | -6.37 | -22.4 | -22.46 | |
P/B Ratio | 0.44 | 0.4 | 0.48 | 0.73 | 0.82 | |
PTB ratio | 0.44 | 0.4 | 0.48 | 0.73 | 0.82 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 7.35 | 8.74 | 5.64 | 4.28 | 5.32 | |
EV to operating cash flow | 6.78 | 12.7 | 7.11 | 9.8 | 5.9 | |
EV to free cash flow | 6.77 | 12.17 | 7.11 | 9.8 | 5.9 | |
Earnings yield | -0.15 | -0.13 | -0.18 | -0.09 | -0.03 | |
Free cash flow yield | -0.19 | -0.12 | -0.16 | -0.04 | -0.04 | |
Debt to equity | 0.01 | 0.01 | 0 | 0 | 0 | |
Debt to assets | 0.01 | 0.01 | 0 | 0 | 0 | |
Net debt to EBITDA | 13.2 | 14.55 | 10.7 | 14.06 | 25.53 | |
Current ratio | 27.05 | 28.07 | 34.94 | 20.35 | 21.89 | |
Interest coverage | 16.47 | 287.23 | 14.34 | 0 | 0 | |
Income quality | 1.14 | 0.79 | 0.81 | 0.49 | 1.29 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.04 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.06 | -1.78 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.36 | 4.41 | 5.26 | 4.35 | 2.77 | |
ROIC | -0.07 | -0.06 | -0.09 | -0.08 | -0.04 | |
Return on tangible assets | -0.06 | -0.05 | -0.08 | -0.06 | -0.03 | |
Graham Net | 4.14 | 3.96 | 3.74 | 3.55 | 3.42 | |
Working capital | 151.53M | 143.89M | 134.43M | 127.33M | 124.67M | |
Tangible asset value | 154.03M | 146.29M | 134.98M | 127.79M | 125.03M | |
Net current asset value | 149.69M | 142.26M | 134.39M | 127.31M | 124.67M | |
Invested capital | 0.01 | 0.01 | 0 | 0 | 0 | |
Average receivables | 114.5K | 8.5K | 126K | 173.5K | 56K | |
Average payables | 2.64M | 1.4M | 901K | 1.01M | 923.5K | |
Average inventory | 0 | 0 | -126K | -173.5K | -56K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 749.7 | 311.41 | 196.95 | 1.21K | 457.2 | |
Days of inventory on hand | 0 | 0 | -73.64 | -85.5 | -15.3 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.12 | 0.29 | 0.46 | 0.07 | 0.2 | |
Inventory turnover | 0 | 0 | -1.22 | -1.05 | -5.88 | |
ROE | -0.07 | -0.05 | -0.09 | -0.07 | -0.03 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
CYT Frequently Asked Questions
What is Cyteir Therapeutics, Inc. stock symbol ?
Cyteir Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol CYT
Is Cyteir Therapeutics, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $2. The lowest prediction is $2 and the highest is $2
What is CYT stock prediction ?
What is Cyteir Therapeutics, Inc. stock quote today ?
Cyteir Therapeutics, Inc. stock price is $3.02 today.
Is Cyteir Therapeutics, Inc. stock public?
Yes, Cyteir Therapeutics, Inc. is a publicly traded company.